# Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

> **NCT00031837** · PHASE3 · TERMINATED · sponsor: **Gary Morrow** · enrollment: 400 (estimated)

## Conditions studied

- Pancreatic Cancer
- Thromboembolism

## Interventions

- **DRUG:** dalteparin
- **DRUG:** gemcitabine hydrochloride
- **PROCEDURE:** quality-of-life assessment

## Key facts

- **NCT ID:** NCT00031837
- **Lead sponsor:** Gary Morrow
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-10
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2015-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00031837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00031837, "Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00031837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*